Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis

Area of Science:

• Dermatology
• Pharmacology
• Clinical Research

Background:

• Isotretinoin (ISO) is a widely prescribed oral retinoid for acne vulgaris.
• While effective, ISO is known to affect numerous human cell types, leading to a range of adverse effects.
• Understanding these adverse events is crucial for patient safety and treatment management.

Purpose of the Study:

• To systematically review and establish the adverse events associated with isotretinoin therapy in human clinical trials.
• To determine the prevalence of these adverse events in patients treated for acne vulgaris.

Main Methods:

• A systematic literature review was conducted from December 2021 to February 2022.
• Searches were performed in PubMed, ClinicalTrials, and Cochrane Library using terms like "isotretinoin acne vulgaris" for studies published between 1980 and 2021.
• Data were extracted from 25 randomized controlled trials (RCTs) and five open-label trials, encompassing 3274 patients.

Main Results:

• Isotretinoin therapy impacts nearly all human body systems, causing a multitude of adverse events.
• The majority of reported adverse events are mild mucocutaneous conditions.
• Severe adverse events are rare, and all identified side effects are reversible and manageable.

Conclusions:

• Isotretinoin treatment for acne vulgaris is associated with a broad spectrum of adverse events.
• These events are generally mild, reversible, and often manageable with specific preparations.
• Adverse events appear to be individual responses to the drug, with severe outcomes being uncommon.